latest news releases from the newsroom
New President of Sandvik Hard Materials
SANDVIKEN, Sweden, Sept. 10, 2003 (PRIMEZONE) -- Tom Erixon has been appointed President of Sandvik Hard Materials and a member of the Sandvik Tooling Management Team as of 1 October, 2003.
ReadSoft signs partner agreement with TietoEnator
STOCKHOLM, Sweden, Sept. 10, 2003 (PRIMEZONE) -- TietoEnator Resource Management has chosen ReadSoft as their main supplier of software for automatic document capture. The new partner agreement concerns the software FORMS and INVOICES in the Nordic countries.
Xention Completes 4 Million Pounds Private Equity Placement
CAMBRIDGE, U.K., Sept. 10, 2003 (PRIMEZONE) -- Xention Discovery Ltd. announced today the closing of a 4 million Pounds ($6.5 million) private equity financing. New investors in the Company include BTG International Ltd. of London; Quester of London; Albany Ventures of Edinburgh and Enterprise Venture Capital Trust plc -- advised by Noble Fund Managers Ltd. -- also of Edinburgh, who join existing investors MVM Ltd and Isis Equity Partners plc. The financing was co-led by BTG and Quester.
Scandinavian Airlines conducts customer testing of biometry
STOCKHOLM, Sweden, Sept. 10, 2003 (PRIMEZONE) -- Using customer testing at two airports, Scandinavian Airlines (Other OTC:SASDF) is taking the next step in its evaluation of biometry for simplified check-in and embarkation. Biometry is the technology that can read a person's unique features, such as fingerprints, face or the iris of the eye.
Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology
LONDON, Sept. 10, 2003 (PRIMEZONE) -- Antisoma plc, (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has in-licensed a programme of telomerase inhibitors from Cancer Research Technology Ltd, the technology transfer arm of the charity Cancer Research UK. This programme was developed by Professor Stephen Neidle, working first at the Institute of Cancer Research and more recently at the University of London School of Pharmacy. Under the licensing agreement, Antisoma has obtained rights to a number of existing molecules and an option on further telomerase inhibitors generated by Professor Neidle's group over the next three years.